ACCELEREATED HYPERFRACTIONATED WITH UNEVEN CRUSHING DAILY DOSE WITH CHEMORADIATION TREATMENT OF INOPERABLE NON-SMALL CELL LUNG CANCER.
This study presents the results of chemoradiation treatment with accelerated hyperfractionated regime with uneven crushing daily dose in patients with unresectable non-small cell lung cancer. The study included 187 patients with confirmed diagnosis of non-small cell lung cancer. Patients were divide...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2016-02-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/258 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | This study presents the results of chemoradiation treatment with accelerated hyperfractionated regime with uneven crushing daily dose in patients with unresectable non-small cell lung cancer. The study included 187 patients with confirmed diagnosis of non-small cell lung cancer. Patients were divided into three groups: the first (control) group included 75 patients who underwent radiotherapy in conventional fractionation regimen (60–66 Gy in 30–33 daily fractions) with sequential 2–4 cycles of chemotherapy of cisplatin + etoposide. In the second (intermediate group) included 66 patients who underwent radiation therapy to hyperfractionated accelerated regimen (1 Gy and 1.5 Gy b.i.d. in 48–56 fractions) with sequential 2–4 cycles of chemotherapy of cisplatin + etoposide. In the third (main) group consisted of 46 patients who underwent radiation therapy to hyperfractionated accelerated regimen (1 Gy and 1.5 Gy b.i.d. in 48–56 fractions) with simultaneous 2 cycles of cisplatin + etoposide. Complete and partial response rate was 60.0 % in the control group, 89.4 % in the intermediate group and 76.0 % in the study group. Five-year overall and disease-free survival rates were in control, intermediate and main groups, 6.6 %, 10.5 %, 21.4 % and 2.5 %, 10.1 %, 16.4 %, respectively. |
|---|---|
| ISSN: | 1814-4861 2312-3168 |